Health Economics and Financing – Resource Allocation, Funding Models, and Value-Based Payment

Definition and Core Concept

This article defines Health Economics as the branch of economics that applies economic principles (scarcity, choice, opportunity cost, efficiency, equity) to the production, distribution, and consumption of health and healthcare services. Health financing refers to the mechanisms by which funds are raised (from taxation, insurance premiums, out-of-pocket payments, or donor contributions), pooled (aggregated to spread risk), and allocated (purchased to pay for services). Core features: (1) resource allocation (deciding which health services to fund, for whom, and in what quantities), (2) efficiency measurement (maximising health outcomes from given resources), (3) cost-effectiveness analysis (CEA) (comparing incremental costs and outcomes across interventions), (4) payment systems (fee-for-service, capitation, diagnosis-related groups – DRGs, bundled payments, value-based payment), (5) equity analysis (examining distribution of health and healthcare across income, geography, race, and other dimensions). The article addresses: stated objectives of health economics and financing; key concepts including opportunity cost, willingness to pay, risk pooling, moral hazard, and adverse selection; core mechanisms such as DRG-based hospital payment, capitation for primary care, and pharmacoeconomic evaluation; international comparisons and debated issues (public vs private financing, cost-effectiveness thresholds, universal health coverage); summary and emerging trends (value-based insurance design, social impact bonds, high-cost patient pooling); and a Q&A section.

1. Specific Aims of This Article

This article describes health economics and financing without endorsing specific policies or payment models. Objectives commonly cited: achieving universal health coverage (access to necessary services without financial hardship), improving efficiency (reducing waste), ensuring financial sustainability, and addressing health inequities. The article notes that global health spending exceeds $8 trillion annually (approximately 10% of global GDP), with substantial variation across countries.

2. Foundational Conceptual Explanations

Key terminology:

• Opportunity cost: The value of the next best alternative foregone when resources are used for one purpose instead of another. Central concept in health economics: spending on healthcare means less spent on education, housing, or other goods.
• Cost-effectiveness analysis (CEA): Method comparing incremental costs and health outcomes (e.g., quality-adjusted life years – QALYs, disability-adjusted life years – DALYs) of alternative interventions. Results expressed as cost per QALY gained.
• Quality-adjusted life year (QALY): Composite measure of length and quality of life (scale 0=deads, 1=perfect health). Used in cost-effectiveness analysis to enable comparisons across different health interventions.
• Moral hazard (health insurance context): Insurance reduces the marginal cost of care, leading to increased consumption of healthcare beyond what would be purchased without insurance (potentially inefficient).
• Risk pooling: Aggregation of health risks across a population so that the healthy subsidise the sick, reducing financial uncertainty for individuals.
• Adverse selection: Tendency for individuals with higher expected healthcare costs to seek insurance coverage, while healthier individuals may opt out, causing premiums to rise and further dissuade healthy enrolment.

Health financing functions (WHO framework):

• Revenue collection: raising funds (taxation, social insurance, private insurance, out-of-pocket).
• Pooling: accumulation and management of funds to spread risk.
• Purchasing: allocating funds to providers (hospitals, clinics, pharmaceuticals) via payment mechanisms.

3. Core Mechanisms and In-Depth Elaboration

Payment mechanisms (provider reimbursement):

• Fee-for-service (FFS): Payment per service (visit, procedure, test). Incentivises volume (potential overutilisation) and higher intensity.
• Capitation: Fixed periodic payment per enrolled patient (e.g., per month per patient). Incentivises efficiency and prevention, may risk under-provision.
• Diagnosis-related groups (DRGs): Fixed payment per hospital admission based on diagnosis, severity, and procedures. Incentivises shorter stays, efficiency, but may risk premature discharge or coding upcoding.
• Bundled payment: Single payment for an episode of care (e.g., joint replacement including hospital, surgeon, anaesthesia, rehabilitation). Encourages coordination across providers.
• Value-based payment (pay-for-performance, shared savings): Bonus payments or penalties based on quality metrics (e.g., blood pressure control, patient satisfaction, readmission rates). Evidence on effectiveness mixed (small improvements of 2-5% for selected metrics).

Cost-effectiveness analysis – application:

• Incremental cost-effectiveness ratio (ICER) = (Cost intervention A – Cost intervention B) / (Health outcome A – Health outcome B).
• Commonly referenced thresholds (not universally accepted):WHO: cost per QALY < 1 x GDP per capita = very cost-effective; 1-3 x GDP per capita = cost-effective.UK NICE: GBP 20,000-30,000 per QALY.US: no official threshold, but $50,000-150,000 per QALY often cited.

Pharmaceutical pricing models:

• Cost-plus pricing (manufacturing cost + markup).
• Value-based pricing (price linked to clinical benefit).
• Reference pricing (price capped based on similar products in other countries).

Universal health coverage (UHC) progress:

• Percentage of population covered by essential health services (UHC service coverage index): global average 68/100 (2021).
• Financial protection (% of population spending >10% of household budget on health): global average 13%, ranging from <1% (France, Germany) to >20% (Nigeria, India).

Effectiveness evidence:

• Systematic review of pay-for-performance (P4P) in healthcare: Small to moderate improvements in process measures (5-10%) and some intermediate outcomes (blood pressure, HbA1c). No consistent effect on mortality or patient-centered outcomes.
• DRG-based hospital payment reduces length of stay (by 10-20%) and increases discharges with no consistent effect on readmission rates.

4. Comprehensive Overview and Objective Discussion

International health financing models:

Debated issues:

1. Cost-effectiveness thresholds (value of a QALY): Different thresholds imply different valuations of health benefit. Higher thresholds (e.g., $150,000/QALY) allow more expensive interventions but lead to higher spending. Lower thresholds may deny beneficial care. No consensus exists.
2. Pharmaceutical pricing (high-cost specialty drug): Annual prices often exceed $50,000-500,000. Cost-effectiveness analyses often exceed typical thresholds, yet payers cover many such drug due to patient demand, clinical guidelines, and political pressure.
3. Financial protection and out-of-pocket payments: High out-of-pocket spending causes financial hardship (catastrophic health expenditure) and deters care-seeking (especially in low- and middle-income countries). Countries with UHC have out-of-pocket shares <20%; those without >40%.
4. Moral hazard in insurance: Deductibles, copayments, and coinsurance reduce moral hazard (decrease spending by 5-20% in RAND Health Insurance Experiment). However, cost-sharing also reduces necessary and unnecessary care similarly. Exemptions for evidence-based preventive care partially addresses this.

5. Summary and Future Trajectories

Summary: Health economics studies resource allocation in healthcare. Financing models include taxation, social insurance, private insurance, and out-of-pocket payments. Payment mechanisms (FFS, capitation, DRGs, value-based) create different provider incentives. Cost-effectiveness analysis compares interventions using cost per QALY. Universal health coverage aims for access without financial hardship.

Emerging trends:

• Value-based insurance design (VBID): Lowering or eliminating cost-sharing for high-value services (e.g., cholesterol medications for individuals with known cardiovascular risk). Improves adherence (5-15%) without increasing total spending (offset by reduced hospital use).
• Social impact bonds (pay-for-success) in health: Private investors fund prevention programmes; government repays if outcomes achieved (e.g., reduced hospitalisations). Limited scale but promising for chronic disease prevention.
• High-cost patient pooling (risk corridors, reinsurance): Government absorbs costs for individuals with extremely high healthcare expenses, reducing premiums in insurance markets.
• Digital health economics (cost-effectiveness of telehealth, apps, AI): Early analyses show telehealth can be cost-effective for selected conditions (diabetes management, mental health) but not universally.

6. Question-and-Answer Session

Q1: Does a higher share of GDP spent on health lead to better population health?
A: At lower spending levels (<500percapita),increasedspendingimproveslifeexpectancyandreducesmortality.Athigherlevels(morethan500percapita),increasedspendingimproveslifeexpectancyandreducesmortality.Athigherlevels(morethan2,000-3,000 per capita), the relationship flattens; spending variation explains little additional health outcome variation. Efficiency and distribution matter more than total amount.

Q2: What is the optimal cost-effectiveness threshold for a healthcare system?
A: No universal optimum. Low-income countries may use 1x GDP per capita (approx 1,000−2,000perQALYforlower−middleincome).High−incomecountriestypicallyuse1,000−2,000perQALYforlower−middleincome).High−incomecountriestypicallyuse50,000-150,000 per QALY. Thresholds reflect societal willingness to pay and opportunity costs.

Q3: Can healthcare be a perfectly competitive market?
A: No. Healthcare has multiple market failures: information asymmetry (physicians know more than patients), externalities (immunisation benefits others), third-party payment (insurance), significant barriers to entry (licensing), and price transparency issues. Regulation is necessary.

Q4: Do higher patient cost-sharing requirements improve healthcare efficiency?
A: They reduce total spending (including necessary and unnecessary care). RAND Health Insurance Experiment showed cost-sharing (25-50%) reduced spending by 20-30% without adverse population health effects (except for low-income sick individuals). However, equity concerns and potential reduction in essential care limit its use.

https://www.who.int/health-economics/
https://www.oecd.org/health/health-systems/
https://www.ispor.org/ (International Society for Pharmacoeconomics)
https://www.rand.org/health-care/health-economics.html